Trial Profile
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-MAP Sub-Study
- 22 Jun 2021 Status changed from active, no longer recruiting to completed.
- 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Dec 2017 New trial record